Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30.
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections.
Telescope Innovations 14-Day RSI Related Terms
TELIF vs VRTX, REGN, ALNY: 14-Day RSI Comparison
For the Biotechnology subindustry, Telescope Innovations's 14-Day RSI, along with its competitors' market caps and 14-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Telescope Innovations 14-Day RSI vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Telescope Innovations's 14-Day RSI distribution charts can be found below:
* The bar in red indicates where Telescope Innovations's 14-Day RSI falls into.
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Telescope Innovations (TELIF) has a 14-Day RSI of 25.55 as of Jul. 20, 2026. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on Telescope Innovations and its competitors. According to the industry distribution chart, Telescope Innovations ranks #41 out of 1424 companies in the Biotechnology industry, placing it in the top 2.9%.
Is Telescope Innovations' 14-Day RSI too high?
Telescope Innovations' current 14-Day RSI is 25.55. The Biotechnology industry median 14-Day RSI is 45.58. Telescope Innovations' value of 25.55 is 43.9% below this industry median. Based on the distribution chart, Telescope Innovations ranks #41 out of 1424 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Telescope Innovations has a GF Score™ of 26/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Telescope Innovations' 14-Day RSI compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Telescope Innovations ranks #41 out of 1424 companies for 14-Day RSI. This places Telescope Innovations in the top 3% of its industry — outperforming the majority of peers. The industry median 14-Day RSI is 45.58. Telescope Innovations' value of 25.55 is 43.9% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 14-Day RSI for a Biotechnology company?
The median 14-Day RSI among Biotechnology companies is 45.58, based on 1,424 companies in the industry. Companies in the top quartile (top 25%) have a 14-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 14-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Telescope Innovations's current 14-Day RSI of 25.55 is 43.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 14-Day RSI mean?
A high 14-Day RSI can signal that a stock is expensive relative to its fundamentals. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on Telescope Innovations and its competitors. For the Biotechnology industry, the median 14-Day RSI is 45.58 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Telescope Innovations's current 14-Day RSI is 25.55. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Telescope Innovations stock overvalued right now?
Based on GuruFocus' analysis, Telescope Innovations (TELIF) is currently considered Modestly Undervalued. The stock's GF Value™ is $0.38, compared to a current price of $0.32 — trading 15.1% below its estimated fair value. The current 14-Day RSI is 25.55 and 43.9% below the Biotechnology industry median of 45.58. Telescope Innovations' overall GF Score™ is 26/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 14-Day RSI calculated?
14-Day RSI is calculated from a company's financial statements. For Telescope Innovations (TELIF), the current 14-Day RSI is 25.55 as of Jul. 20, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Telescope Innovations (TELIF) Overvalued in 2026?
Based on GuruFocus' analysis, Telescope Innovations stock appears to be undervalued.
The current stock price of $0.32 is trading 15.1% below its estimated GF Value™ of $0.38.
GuruFocus considers Telescope Innovations to be Modestly Undervalued.
Key valuation signals for TELIF:
14-Day RSI: 25.55
GF Value™: $0.38 vs. price of $0.32 (15.1% below fair value)
Industry Position: 43.9% below the Biotechnology median (#41 of 1424)
No single metric tells the full story. See the TELIF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Telescope Innovations Corp is a technology company focused on development as a Contract Research Organization (CRO) to develop intellectual property, provide contract research, and build automation products, and operates as a chemical technology company developing scalable manufacturing processes and tools for the pharmaceutical and chemical industry. Its flagship product is the DirectInject-LC system. The Company operates in a single operating segment and generates revenue from three streams: contract research services, grant income, and the sale of automation products, with the majority of revenue derived from automation product sales from customer contracts. It operates in Canada, the United States, Europe, and Asia, with the majority of revenue coming from the United States.
26GF Score
Get the complete analysis for TELIF
14-Day RSI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TELIF has been successfully added to your 
